DC
BCYC

Davenport & Co’s Bicycle Therapeutics BCYC Stock Holding History

Davenport & Co’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,650
Closed -$467K – 1159
2024
Q3 		$467K Buy
+20,650
New +$476K ﹤0.01% 849

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Davenport & Co's BCYC Position: Q4 2024 in Review

Davenport & Co sold out of Bicycle Therapeutics (BCYC) in Q4 2024, closing a stake of 20,650 shares — an estimated $467K sold.

Davenport & Co first reported a position in BCYC in Q3 2024 and held it in 1 quarter. The position peaked at $467K in Q3 2024. 97 funds tracked by Wall St. Rank hold BCYC as of Q4 2024.

  • Davenport & Co reported no remaining Bicycle Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Davenport & Co sold 20,650 Bicycle Therapeutics shares in Q4 2024, an estimated $467K.
  • Davenport & Co first reported a position in Bicycle Therapeutics in Q3 2024 and held it in 1 quarter.
  • Davenport & Co's Bicycle Therapeutics position peaked at $467K in Q3 2024.
  • 97 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2024.

Based on Davenport & Co's 13F filing for Q4 2024, filed 24 Jan 2025.